FDA accepts NDA for elinzanetant for the treatment of moderate-to-severe vasomotor symptoms
Bayer announced that the FDA has accepted the company’s New Drug Application (NDA) for the investigational compound elinzanetant seeking approval for the treatment of moderate-to-severe vasomotor symptoms (VMS, also known as hot flashes) associated with menopause
“The NDA acceptance of elinzanetant by the FDA marks a significant milestone in our efforts to advance menopause care for women in the U.S.,” said Christine Roth, Executive Vice President, Global Product Strategy and Commercialization, Member of the Pharmaceutical Leadership Team at Bayer. “If approved, elinzanetant will offer a new non-hormonal option to women seeking treatment for moderate to severe vasomotor symptoms and we look forward to the review by the agency."
The NDA application is based on the positive results from the OASIS 1, 2 and 3 Phase III studies evaluating the efficacy and safety of the investigational compound elinzanetant versus placebo. Findings from OASIS 1 and 2 were published in August 2024 in JAMA.0F Detailed results of the Phase III study OASIS 3 providing supporting efficacy and additional long-term safety data were presented at The Menopause Society (TMS) annual meeting in September 2024.
Citation: "Elinzanetant for the Treatment of Vasomotor Symptoms Associated With MenopauseOASIS 1 and 2 Randomized Clinical Trials"- JoAnn V. Pinkerton, MD, MSCP; James A. Simon, MD, MSCP; Hadine Joffe, MD, MSc; et alPauline M. Maki, PhD; Rossella E. Nappi, MD, PhD; Nick Panay, BSc, MBBS; Claudio N. Soares, MD, PhD, MBA; Rebecca C. Thurston, PhD; Cecilia Caetano, MD; Claudia Haberland, PhD; et al.,; JAMA. Published online August 22, 2024. doi:10.1001/jama.2024.14618.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins